• Something wrong with this record ?

Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

J. Tromp, BL. Claggett, J. Liu, AM. Jackson, PS. Jhund, L. Køber, J. Widimský, SA. Boytsov, VK. Chopra, IS. Anand, J. Ge, CH. Chen, AP. Maggioni, F. Martinez, M. Packer, MA. Pfeffer, B. Pieske, MM. Redfield, JL. Rouleau, DJ. Van Veldhuisen, F....

. 2021 ; 14 (4) : e007901. [pub] 20210419

Language English Country United States

Document type Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22004481

Grant support
KL2 TR001424 NCATS NIH HHS - United States
P30 AG059988 NIA NIH HHS - United States
P30 DK092923 NIDDK NIH HHS - United States
R21 HL085375 NHLBI NIH HHS - United States
T32 HL069771 NHLBI NIH HHS - United States

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem with important regional differences. We investigated these differences in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF), the largest and most inclusive global HFpEF trial. METHODS: We studied differences in clinical characteristics, outcomes, and treatment effects of sacubitril/valsartan in 4796 patients with HFpEF from the PARAGON-HF trial, grouped according to geographic region. RESULTS: Regional differences in patient characteristics and comorbidities were observed: patients from Western Europe were oldest (mean 75±7 years) with the highest prevalence of atrial fibrillation/flutter (36%); Central/Eastern European patients were youngest (mean 71±8 years) with the highest prevalence of coronary artery disease (50%); North American patients had the highest prevalence of obesity (65%) and diabetes (49%); Latin American patients were younger (73±9 years) and had a high prevalence of obesity (53%); and Asia-Pacific patients had a high prevalence of diabetes (44%), despite a low prevalence of obesity (26%). Rates of the primary composite end point of total hospitalizations for HF and death from cardiovascular causes were lower in patients from Central Europe (9 per 100 patient-years) and highest in patients from North America (28 per 100 patient-years), which was primarily driven by a greater number of total hospitalizations for HF. The effect of treatment with sacubitril-valsartan was not modified by region (interaction P>0.05). CONCLUSIONS: Among patients with HFpEF recruited worldwide in PARAGON-HF, there were important regional differences in clinical characteristics and outcomes, which may have implications for the design of future clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.

1st Faculty of Medicine Charles University Prague Czech Republic

Associazione Nazionale Medici Cardiologi Ospedalieri Florence Italy

Baylor Heart and Vascular Institute Baylor University Medical Center Dallas TX

British Heart Foundation Cardiovascular Research Centre Institute of Cardiovascular and Medical Sciences University of Glasgow United Kingdom

Cardiovascular Division Brigham and Women's Hospital Harvard Medical School Boston MA

Department of Cardiology Heart Centre Rigshospitalet Copenhagen University Hospital Denmark

Department of Cardiology University Medical Centre Groningen University of Groningen the Netherlands

Department of Cardiovascular Medicine Mayo Clinic Rochester MN

Department of Internal Medicine Cardiology Charité Universitaetsmedizin Berlin Campus Virchow Klinikum Berlin Germany

Department of Medicine VA Medical Center and University of Minnesota Minneapolis

Duke NUS Medical School Singapore

Faculty of Medicine National Yang Ming University Taipei Taiwan Republic of China

Heart Failure and Research Max Super Specialty Hospital Saket New Delhi India

Inserm CIC 1433 and Université de Lorraine Centre Hospitalier Régional Universitaire Nancy France

Institut de Cardiologie de Montréal Université de Montréal QC Canada

Medical University of South Carolina and Ralph H Johnson Veterans Administration Medical Center Charleston

National Heart Centre Singapore

National Research Center for Cardiology of the Ministry of Health of the Russian Federation Moscow

Novartis Pharmaceuticals Corporation East Hanover NJ

Saw Swee Hock School of Public Health National University of Singapore Singapore

Shanghai Institute of Cardiovascular Diseases Zhongshan Hospital Fudan University China

Universidad Nacional of Cordoba Argentina

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004481
003      
CZ-PrNML
005      
20240910100721.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCHEARTFAILURE.120.007901 $2 doi
035    __
$a (PubMed)33866828
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tromp, Jasper $u National Heart Centre Singapore $u Duke-NUS Medical School, Singapore $u Department of Cardiology, University Medical Centre Groningen, University of Groningen, the Netherlands $u Saw Swee Hock School of Public Health, National University of Singapore, Singapore
245    10
$a Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial / $c J. Tromp, BL. Claggett, J. Liu, AM. Jackson, PS. Jhund, L. Køber, J. Widimský, SA. Boytsov, VK. Chopra, IS. Anand, J. Ge, CH. Chen, AP. Maggioni, F. Martinez, M. Packer, MA. Pfeffer, B. Pieske, MM. Redfield, JL. Rouleau, DJ. Van Veldhuisen, F. Zannad, MR. Zile, AR. Rizkala, A. Inubushi-Molessa, MP. Lefkowitz, VC. Shi, JJV. McMurray, SD. Solomon, CSP. Lam, PARAGON-HF Investigators
520    9_
$a BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem with important regional differences. We investigated these differences in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF), the largest and most inclusive global HFpEF trial. METHODS: We studied differences in clinical characteristics, outcomes, and treatment effects of sacubitril/valsartan in 4796 patients with HFpEF from the PARAGON-HF trial, grouped according to geographic region. RESULTS: Regional differences in patient characteristics and comorbidities were observed: patients from Western Europe were oldest (mean 75±7 years) with the highest prevalence of atrial fibrillation/flutter (36%); Central/Eastern European patients were youngest (mean 71±8 years) with the highest prevalence of coronary artery disease (50%); North American patients had the highest prevalence of obesity (65%) and diabetes (49%); Latin American patients were younger (73±9 years) and had a high prevalence of obesity (53%); and Asia-Pacific patients had a high prevalence of diabetes (44%), despite a low prevalence of obesity (26%). Rates of the primary composite end point of total hospitalizations for HF and death from cardiovascular causes were lower in patients from Central Europe (9 per 100 patient-years) and highest in patients from North America (28 per 100 patient-years), which was primarily driven by a greater number of total hospitalizations for HF. The effect of treatment with sacubitril-valsartan was not modified by region (interaction P>0.05). CONCLUSIONS: Among patients with HFpEF recruited worldwide in PARAGON-HF, there were important regional differences in clinical characteristics and outcomes, which may have implications for the design of future clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.
650    _2
$a senioři $7 D000368
650    _2
$a aminobutyráty $x terapeutické užití $7 D000613
650    _2
$a antagonisté receptorů pro angiotenzin $x terapeutické užití $7 D057911
650    _2
$a bifenylové sloučeniny $x terapeutické užití $7 D001713
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a ženské pohlaví $7 D005260
650    12
$a celosvětové zdraví $7 D014943
650    _2
$a srdeční selhání $x farmakoterapie $x mortalita $x patofyziologie $7 D006333
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neprilysin $x terapeutické užití $7 D015260
650    _2
$a kvalita života $7 D011788
650    _2
$a rizikové faktory $7 D012307
650    12
$a tepový objem $7 D013318
650    _2
$a valsartan $x terapeutické užití $7 D000068756
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Claggett, Brian L $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
700    1_
$a Liu, Jiankang $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
700    1_
$a Jackson, Alice M $u British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom
700    1_
$a Jhund, Pardeep S $u British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom
700    1_
$a Køber, Lars $u Department of Cardiology, Heart Centre, Rigshospitalet, Copenhagen University Hospital, Denmark
700    1_
$a Widimský, Jiří $u First Faculty of Medicine, Charles University Prague, Czech Republic
700    1_
$a Boytsov, Sergey A $u National Research Center for Cardiology of the Ministry of Health of the Russian Federation, Moscow
700    1_
$a Chopra, Vijay K $u Heart Failure and Research Max Super Specialty Hospital Saket, New Delhi, India
700    1_
$a Anand, Inder S. $u Department of Medicine, VA Medical Center and University of Minnesota, Minneapolis $7 xx0322272
700    1_
$a Ge, Junbo $u Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China
700    1_
$a Chen, Chen-Huan $u Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China
700    1_
$a Maggioni, Aldo P $u Associazione Nazionale Medici Cardiologi Ospedalieri, Florence, Italy
700    1_
$a Martinez, Felipe $u Universidad Nacional of Cordoba, Argentina
700    1_
$a Packer, Milton $u Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX
700    1_
$a Pfeffer, Marc A $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
700    1_
$a Pieske, Burkert $u Department of Internal Medicine, Cardiology Charité, Universitaetsmedizin Berlin, Campus Virchow Klinikum Berlin, Germany
700    1_
$a Redfield, Margaret M $u Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN
700    1_
$a Rouleau, Jean L $u Institut de Cardiologie de Montréal, Université de Montréal, QC, Canada
700    1_
$a Van Veldhuisen, Dirk J $u Department of Cardiology, University Medical Centre Groningen, University of Groningen, the Netherlands
700    1_
$a Zannad, Faiez $u Inserm CIC 1433 and Université de Lorraine, Centre Hospitalier Régional Universitaire, Nancy, France (F.Z.)
700    1_
$a Zile, Michael R $u Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston (M.R.Z.)
700    1_
$a Rizkala, Adel R $u Novartis Pharmaceuticals Corporation, East Hanover, NJ (A.R.R., A.I.-M., M.P.L., V.C.S.)
700    1_
$a Inubushi-Molessa, Akiko $u Novartis Pharmaceuticals Corporation, East Hanover, NJ (A.R.R., A.I.-M., M.P.L., V.C.S.)
700    1_
$a Lefkowitz, Martin P $u Novartis Pharmaceuticals Corporation, East Hanover, NJ (A.R.R., A.I.-M., M.P.L., V.C.S.)
700    1_
$a Shi, Victor C $u Novartis Pharmaceuticals Corporation, East Hanover, NJ (A.R.R., A.I.-M., M.P.L., V.C.S.)
700    1_
$a McMurray, John J V $u British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (A.M.J., P.S.J., J.J.V.M.)
700    1_
$a Solomon, Scott D $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.L.C., J.L., M.A.P., S.D.S.)
700    1_
$a Lam, Carolyn S P $u National Heart Centre Singapore (J.T., C.S.P.L.) $u Duke-NUS Medical School, Singapore (J.T., C.S.P.L.) $u Department of Cardiology, University Medical Centre Groningen, University of Groningen, the Netherlands (J.T., D.J.V.V., C.S.P.L.)
710    2_
$a PARAGON-HF Investigators
773    0_
$w MED00159985 $t Circulation. Heart failure $x 1941-3297 $g Roč. 14, č. 4 (2021), s. e007901
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33866828 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20240910100718 $b ABA008
999    __
$a ok $b bmc $g 1751826 $s 1155630
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 14 $c 4 $d e007901 $e 20210419 $i 1941-3297 $m Circulation. Heart failure $n Circ Heart Fail $x MED00159985
GRA    __
$a KL2 TR001424 $p NCATS NIH HHS $2 United States
GRA    __
$a P30 AG059988 $p NIA NIH HHS $2 United States
GRA    __
$a P30 DK092923 $p NIDDK NIH HHS $2 United States
GRA    __
$a R21 HL085375 $p NHLBI NIH HHS $2 United States
GRA    __
$a T32 HL069771 $p NHLBI NIH HHS $2 United States
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options